CHRS
Price
$0.74
Change
+$0.01 (+1.37%)
Updated
Jun 27 closing price
Capitalization
86.15M
31 days until earnings call
XNCR
Price
$8.14
Change
-$0.26 (-3.10%)
Updated
Jun 27 closing price
Capitalization
579.33M
31 days until earnings call
Interact to see
Advertisement

CHRS vs XNCR

Header iconCHRS vs XNCR Comparison
Open Charts CHRS vs XNCRBanner chart's image
Coherus Oncology
Price$0.74
Change+$0.01 (+1.37%)
Volume$1.78M
Capitalization86.15M
Xencor
Price$8.14
Change-$0.26 (-3.10%)
Volume$1.62M
Capitalization579.33M
CHRS vs XNCR Comparison Chart in %
Loading...
CHRS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
XNCR
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
CHRS vs. XNCR commentary
Jun 30, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CHRS is a Buy and XNCR is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Jun 30, 2025
Stock price -- (CHRS: $0.74 vs. XNCR: $8.14)
Brand notoriety: CHRS and XNCR are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CHRS: 126% vs. XNCR: 171%
Market capitalization -- CHRS: $86.15M vs. XNCR: $579.33M
CHRS [@Biotechnology] is valued at $86.15M. XNCR’s [@Biotechnology] market capitalization is $579.33M. The market cap for tickers in the [@Biotechnology] industry ranges from $304.6B to $0. The average market capitalization across the [@Biotechnology] industry is $2.3B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CHRS’s FA Score shows that 0 FA rating(s) are green whileXNCR’s FA Score has 1 green FA rating(s).

  • CHRS’s FA Score: 0 green, 5 red.
  • XNCR’s FA Score: 1 green, 4 red.
According to our system of comparison, XNCR is a better buy in the long-term than CHRS.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CHRS’s TA Score shows that 3 TA indicator(s) are bullish while XNCR’s TA Score has 2 bullish TA indicator(s).

  • CHRS’s TA Score: 3 bullish, 4 bearish.
  • XNCR’s TA Score: 2 bullish, 7 bearish.
According to our system of comparison, CHRS is a better buy in the short-term than XNCR.

Price Growth

CHRS (@Biotechnology) experienced а -0.55% price change this week, while XNCR (@Biotechnology) price change was -4.68% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +4.13%. For the same industry, the average monthly price growth was +31.22%, and the average quarterly price growth was +12.91%.

Reported Earning Dates

CHRS is expected to report earnings on Jul 31, 2025.

XNCR is expected to report earnings on Jul 30, 2025.

Industries' Descriptions

@Biotechnology (+4.13% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
XNCR($579M) has a higher market cap than CHRS($86.2M). CHRS YTD gains are higher at: -46.152 vs. XNCR (-64.578). CHRS has higher annual earnings (EBITDA): 80.2M vs. XNCR (-161.68M). XNCR has more cash in the bank: 470M vs. CHRS (82.4M). XNCR has less debt than CHRS: XNCR (67.8M) vs CHRS (270M). CHRS has higher revenues than XNCR: CHRS (272M) vs XNCR (127M).
CHRSXNCRCHRS / XNCR
Capitalization86.2M579M15%
EBITDA80.2M-161.68M-50%
Gain YTD-46.152-64.57871%
P/E Ratio1.68N/A-
Revenue272M127M214%
Total Cash82.4M470M18%
Total Debt270M67.8M398%
FUNDAMENTALS RATINGS
CHRS vs XNCR: Fundamental Ratings
CHRS
XNCR
OUTLOOK RATING
1..100
7673
VALUATION
overvalued / fair valued / undervalued
1..100
90
Overvalued
78
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
10097
PRICE GROWTH RATING
1..100
8865
P/E GROWTH RATING
1..100
974
SEASONALITY SCORE
1..100
15n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

XNCR's Valuation (78) in the Biotechnology industry is in the same range as CHRS (90). This means that XNCR’s stock grew similarly to CHRS’s over the last 12 months.

XNCR's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as CHRS (100). This means that XNCR’s stock grew similarly to CHRS’s over the last 12 months.

XNCR's SMR Rating (97) in the Biotechnology industry is in the same range as CHRS (100). This means that XNCR’s stock grew similarly to CHRS’s over the last 12 months.

XNCR's Price Growth Rating (65) in the Biotechnology industry is in the same range as CHRS (88). This means that XNCR’s stock grew similarly to CHRS’s over the last 12 months.

XNCR's P/E Growth Rating (4) in the Biotechnology industry is significantly better than the same rating for CHRS (97). This means that XNCR’s stock grew significantly faster than CHRS’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CHRSXNCR
RSI
ODDS (%)
N/A
N/A
Stochastic
ODDS (%)
Bullish Trend 3 days ago
79%
Bullish Trend 3 days ago
68%
Momentum
ODDS (%)
Bearish Trend 3 days ago
84%
Bearish Trend 3 days ago
83%
MACD
ODDS (%)
Bullish Trend 3 days ago
79%
Bearish Trend 3 days ago
84%
TrendWeek
ODDS (%)
Bearish Trend 3 days ago
89%
Bearish Trend 3 days ago
83%
TrendMonth
ODDS (%)
Bearish Trend 3 days ago
88%
Bullish Trend 3 days ago
74%
Advances
ODDS (%)
Bullish Trend 3 days ago
71%
Bullish Trend 10 days ago
71%
Declines
ODDS (%)
Bearish Trend 17 days ago
88%
Bearish Trend 3 days ago
81%
BollingerBands
ODDS (%)
Bearish Trend 3 days ago
90%
Bearish Trend 3 days ago
69%
Aroon
ODDS (%)
Bearish Trend 3 days ago
85%
Bearish Trend 3 days ago
88%
View a ticker or compare two or three
Interact to see
Advertisement
CHRS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
XNCR
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
RGELX11.400.12
+1.06%
RBC Global Equity Leaders A
JLCVX73.020.43
+0.59%
JHancock Fundamental Large Cap Core R5
MGTCX9.320.02
+0.22%
Transamerica Mid Cap Growth C
WHGOX12.100.01
+0.10%
Westwood Income Opportunity Ultra
VARBX10.91N/A
N/A
First Trust Merger Arbitrage Cl I

XNCR and

Correlation & Price change

A.I.dvisor indicates that over the last year, XNCR has been loosely correlated with CRNX. These tickers have moved in lockstep 58% of the time. This A.I.-generated data suggests there is some statistical probability that if XNCR jumps, then CRNX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To XNCR
1D Price
Change %
XNCR100%
-3.10%
CRNX - XNCR
58%
Loosely correlated
-0.10%
BEAM - XNCR
56%
Loosely correlated
-1.98%
KRYS - XNCR
55%
Loosely correlated
-2.60%
BCYC - XNCR
55%
Loosely correlated
-0.55%
SYRE - XNCR
55%
Loosely correlated
-4.99%
More